• Explore /
  • Poster
  • / Real-world survival outcomes of patients (pts) treated with 6-weekly pembrolizumab 400mg (pem6w) plus axitinib (axi) for advanced renal cell carcinoma (aRCC).

Real-world survival outcomes of patients (pts) treated with 6-weekly pembrolizumab 400mg (pem6w) plus axitinib (axi) for advanced renal cell carcinoma (aRCC).

Abstract Poster

Authors

null

Sonam Ansel

Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

Sonam Ansel , Mark Stares , Robert J. Jones , Stefan N. Symeonides , Laura Manson , Anirban Ray-Chaudhuri , Manreet Randhawa , Sarah Slater , Abeera Devasar , Jahangeer Malik , Aravindhan Sundaramurthy , Tony Elliott , Balaji Venugopal

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer

Sub Track

Quality of Care/Quality Improvement and Real-World Evidence

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr 645)

DOI

10.1200/JCO.2023.41.6_suppl.645

Abstract #

645

Poster Bd #

F15

Abstract Disclosures

Similar Posters

First Author: Bradley Alexander McGregor

First Author: Xiting Cao

First Author: Paul D. Nathan

First Author: Carissa Beaulieu